LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Apellis Pharmaceuticals Inc

Suletud

SektorTervishoid

17.46 7.05

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

16.22

Max

17.77

Põhinäitajad

By Trading Economics

Sissetulek

-56M

-92M

Müük

-46M

167M

Aktsiakasum

-0.74

Kasumimarginaal

-55.292

Töötajad

705

EBITDA

-56M

-80M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+129.22% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

31. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-385M

2.2B

Eelmine avamishind

10.41

Eelmine sulgemishind

17.46

Uudiste sentiment

By Acuity

17%

83%

24 / 382 Pingereas Healthcare

Apellis Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

15. mai 2025, 22:52 UTC

Tulu
Suurimad hinnamuutused turgudel

Virgin Galactic Shares Rise on Commercial Spaceflight Plans, Narrower 1Q Loss

15. mai 2025, 20:37 UTC

Peamised uudised
Tulu

Applied Materials Logs Higher 2Q Profit, Revenue as Customer Demand Remains Unchanged

16. mai 2025, 00:00 UTC

Market Talk

Xero Bull Stays Positive on Cost Outlook -- Market Talk

15. mai 2025, 23:47 UTC

Market Talk

Gold Consolidates; Likely Supported by Signs of Disinflation -- Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15. mai 2025, 23:38 UTC

Market Talk

Nikkei May Edge Higher, Tracking Gains Across Most U.S. Equity Markets -- Market Talk

15. mai 2025, 23:14 UTC

Peamised uudised

Walmart Becomes Biggest Retailer Yet to Pass Through Tariff Price Increases -- 4th Update

15. mai 2025, 22:46 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Working With Restructuring Advisers Latham, AlixPartners to Explore Options for Monsanto -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Exec Says Company Committed to Resolving Roundup Lawsuits in 18 Months -- WSJ

15. mai 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Bayer Seeks New Roundup Settlement While Exploring Monsanto Bankruptcy -- WSJ

15. mai 2025, 21:58 UTC

Tulu

Applied Materials Earnings Beat Expectations. Why the Stock Is Down. -- Barrons.com

15. mai 2025, 21:24 UTC

Tulu

Cava's Earnings Beat Expectations. Growth Was Strong Despite Tariff Fears. -- Barrons.com

15. mai 2025, 20:56 UTC

Market Talk

U.S. Spending Downturn Could Lie Ahead -- Market Talk

15. mai 2025, 20:54 UTC

Market Talk
Tulu

Applied Materials CFO Says Demand Stable Despite Tariffs, Macro -- Market Talk

15. mai 2025, 20:54 UTC

Tulu

Applied Materials Investing to Support Semiconductor Market of More Than $1T by End of Decade, Financial Chief Says

15. mai 2025, 20:51 UTC

Tulu

Applied Materials Financial Chief: Long-Term Secular Growth Drivers Remain Intact

15. mai 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

15. mai 2025, 20:50 UTC

Omandamised, ülevõtmised, äriostud

Berkshire Sells Financial Stocks, Doubles Constellation Stake, Holds Steady on Apple -- WSJ

15. mai 2025, 20:50 UTC

Tulu

Applied Materials' Customer Investments Continue at Expected Rate and Pace, Financial Chief Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Not Currently Seeing Large Changes in Customer Demand, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Sees Revenue From Advanced DRAM Customers to Grow 40% in FY25, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Grew Faster Than Peers in Markets Outside China in 2Q, CEO Says

15. mai 2025, 20:47 UTC

Tulu

Applied Materials Underperformed Market in China in 2Q Due to Restrictions on U.S. Companies, CEO Says

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Growth Was Fueled by Robust Domestic Demand and Expansion of Pdt Portfolio to Include Rubber and Coal >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Declined to $9.3M From $18.9M in FY23, Dip Was Attributed to the Temporary Shutdown of Texas Mining Facility for Upgrades During 1H 2024 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: FY24 Significant Yr-over-Yr Increase in Commodity Trading Rev, Which Soared to $214.3M FY24, 92.6% of Total Rev Up From 74.0% in FY23 >SOS

15. mai 2025, 20:37 UTC

Tulu

SOS Ltd: Cryptocurrency Mining Rev Halves as SOS Focuses on Facility Upgrades and Commodity Expansion >SOS

15. mai 2025, 20:26 UTC

Peamised uudised

Trump Presses Apple to Bring iPhone Manufacturing to America. Wall Street Shrugs. -- WSJ

15. mai 2025, 20:25 UTC

Tulu

Deere Stock Jumps on Guidance Cut. Here's Why. -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Apellis Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

129.22% tõus

12 kuu keskmine prognoos

Keskmine 37.5 USD  129.22%

Kõrge 60 USD

Madal 18 USD

Põhineb 21 Wall Streeti analüütiku instrumendi Apellis Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

21 ratings

13

Osta

8

Hoia

0

Müü

Sentiment

By Acuity

24 / 382 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Apellis Pharmaceuticals Inc

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.